Model of translational cancer research in multiple myeloma
Open Access
- 19 July 2012
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 103 (11), 1907-1912
- https://doi.org/10.1111/j.1349-7006.2012.02384.x
Abstract
Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in multiple myeloma (MM). The introduction of novel agents such as the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide, which were rapidly translated from preclinical studies at the Dana‐Farber Cancer Institute into clinical trials, has changed the treatment paradigm and markedly extended overall survival; MM has therefore become a remarkable example of translational cancer research in new drug development. In this article, with the aim of determining the key factors underlying success in translational research, we focus on our studies of MM at Dana‐Farber Cancer Institute as well as at our institutes. The identification of these key factors will help to promote translational cancer research not only in MM but also in other hematologic malignancies and solid tumors, to develop novel therapies, to overcome drug resistance, and to thereby improve the prognosis of cancer patients. (Cancer Sci, doi: 10.1111/j.1349‐7006.2012.02384.x, 2012)Keywords
This publication has 71 references indexed in Scilit:
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma CellsClinical Cancer Research, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Defining Translational Research: Implications for TrainingAcademic Medicine, 2010
- A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple MyelomaClinical Cancer Research, 2009
- The cancer genomeNature, 2009
- Retraction: Fatty acid synthase is a novel therapeutic target in multiple myelomaBritish Journal of Haematology, 2008
- Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2007
- The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2006
- Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Proceedings of the National Academy of Sciences of the United States of America, 2006